Guidance

Mpox vaccine PGD template (previously named smallpox vaccine PGD)

PGD template for administering mpox vaccine in response to mpox (monkeypox).

Applies to England

Documents

Mpox patient group direction (PGD) template

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This mpox patient group direction (PGD) template (previously known as smallpox vaccine PGD) supports the administration of the mpox vaccine, modified vaccina virus Ankara-Bavarian Nordic (MVA-BN), to individuals identified for immunisation in response to mpox incidents and routine vaccination ( see JCVI recommendations 10 November 2023).

The mpox PGD version 4.00 is valid from 10 October 2024 to 30 April 2027.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy/procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and Summary of Product Characteristics for the vaccine.

Updates to this page

Published 5 August 2022
Last updated 14 October 2024 + show all updates
  1. Added mpox PGD version 4 - see page 3 for change history.

  2. Added 'Notice of extension of the validity of smallpox vaccine PGD'.

  3. Added version 3 - see page 2 for change history.

  4. Added version 2.00 – details of changes on page 2 and updated batch information.

  5. Corrected review date.

  6. First published.

Sign up for emails or print this page